| News

Noema Pharma raises 54 million Swiss francs

01.12.2020

The Basel-based pharmaceutical company Noema Pharma has raised a total of 54 million Swiss francs as part of a Series A financing round. This should help to advance the clinical development of drugs aimed at fighting rare neurological disorders.

Noema Pharma develops drugs to treat rare neurological disorders that arise on account of imbalanced neuronal networks. Clinical development can now be advanced for four relevant product candidates after Noema Pharma successfully closed a financing round by raising a total of 54 million Swiss francs, as detailed in a press release. In addition, the Basel-based pharma group Roche has now received a shareholding in Noema in exchange for rights to the four product candidates. These aim to combat “seizures in tuberous sclerosis complex (TSC), trigeminal neuralgia, Tourette syndrome and other rare neurological disorders”.

“The successful licensing of these exciting clinical-stage product candidates from Roche, together with our up-sized CHF 54 million Series A financing, will enable Noema to reach value-creating development milestones with all four products”, comments Luigi Costa, CEO of Noema, in the press release, before adding: “We are honored to have garnered continued support from our seed investor, Sofinnova Partners, and to have attracted Polaris Partners as a co-lead investor. We are equally pleased to welcome highly experienced specialist investors Gilde Healthcare, Invus and BioMed Partners”.

Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, and Darren Carroll, Partner at Polaris Partners, will both become members of the newly formed Board of Directors at Noema Pharma. While Papiernik underlined the work conducted by Noema up to this point that has aimed “to bring ground-breaking therapies to patients with debilitating neurological disorders”, Carroll, for his part, described the company as a “prime example of the exceptional pharma-grade assets Europe has to offer, along with a flourishing talent pool”.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Basel Area – exactly the right chemistry for South Korean pharma companies
Basel Area Business & Innovation, Innovation, Invest

Basel Area – exactly the right chemistry for South Korean pharma companies

KPBMA and Basel Area Business & Innovation establish tailored collaboration to support Korean biopharmaceutical companies to enter the European market

Read More
Basel Area supporting three digital health startups
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Basel Area supporting three digital health startups

Basel Area Business & Innovation will be offering intensive support to the three winners of its DayOne Digital Health Accelerator...

Read More
Gray establishes presence in Basel
Basel Area Business & Innovation, Innovation, Invest

Gray establishes presence in Basel

The North American fully integrated specialty service provider Gray has established a subsidiary in Basel. The key factors in favor...

Read More
Artificial Intelligence able to identify potentially life-saving antibiotics
Basel Area Business & Innovation, Innovation, Invest

Artificial Intelligence able to identify potentially life-saving antibiotics

A computer algorithm has identified antibiotics that that are still effective against infections in which multi-resistant germs are present. University...

Read More
Investors give Anaveon 110 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest

Investors give Anaveon 110 million Swiss francs

Anaveon has received investment commitments amounting to 110 million Swiss francs in a Serie B funding round. The Basel-based biopharmaceutical...

Read More
Basel alliance seeks to combat antibiotic resistance
Basel Area Business & Innovation, Innovation, Invest

Basel alliance seeks to combat antibiotic resistance

The Spearhead alliance has been founded in Basel with the aim of combating the silent pandemic of antimicrobial resistance. By...

Read More
1 2 3 52

Do you have a question? We'd like to hear from you.